作者
AP Kiess, SR Banerjee, RC Mease, SP Rowe, A Rao, CA Foss, Y Chen, X Yang, SY Cho, S Nimmagadda, MG Pomper
发表日期
2015/9
来源
The quarterly journal of nuclear medicine and molecular imaging: official publication of the Italian Association of Nuclear Medicine (AIMN)[and] the International Association of Radiopharmacology (IAR),[and] Section of the Society of...
卷号
59
期号
3
页码范围
241
出版商
NIH Public Access
简介
The prostate-specific membrane antigen (PSMA) is a molecular target whose use has resulted in some of the most productive work toward imaging and treating prostate cancer over the past two decades. A wide variety of imaging agents extending from intact antibodies to low-molecular-weight compounds permeate the literature. In parallel there is a rapidly expanding pool of antibody-drug conjugates, radiopharmaceutical therapeutics, small-molecule drug conjugates, theranostics and nanomedicines targeting PSMA. Such productivity is motivated by the abundant expression of PSMA on the surface of prostate cancer cells and within the neovasculature of other solid tumors, with limited expression in most normal tissues. Animating the field is a variety of small-molecule scaffolds upon which the radionuclides, drugs, MR-detectable species and nanoparticles can be placed with relative ease. Among those, the urea …
学术搜索中的文章
AP Kiess, SR Banerjee, RC Mease, SP Rowe, A Rao… - The quarterly journal of nuclear medicine and …, 2015